CY2356B1 - Form III crystalline {r-(r*,r*)}-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-{(phenylamino)carbonyl}-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin). - Google Patents
Form III crystalline {r-(r*,r*)}-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-{(phenylamino)carbonyl}-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin).Info
- Publication number
- CY2356B1 CY2356B1 CY0300020A CY0300020A CY2356B1 CY 2356 B1 CY2356 B1 CY 2356B1 CY 0300020 A CY0300020 A CY 0300020A CY 0300020 A CY0300020 A CY 0300020A CY 2356 B1 CY2356 B1 CY 2356B1
- Authority
- CY
- Cyprus
- Prior art keywords
- atorvastatin
- phenylamino
- fluorophenyl
- pyrrole
- dihydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60145495A | 1995-07-17 | 1995-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY2356B1 true CY2356B1 (en) | 2004-06-04 |
Family
ID=24407538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY0300020A CY2356B1 (en) | 1995-07-17 | 2003-03-06 | Form III crystalline {r-(r*,r*)}-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-{(phenylamino)carbonyl}-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin). |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0848704B2 (de) |
CY (1) | CY2356B1 (de) |
DE (1) | DE69616358T2 (de) |
PT (1) | PT848704E (de) |
SI (1) | SI0848704T1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) |
BRPI0610344A2 (pt) | 2005-12-13 | 2016-11-29 | Teva Pharma | forma cristalizada do atorvastatin hemi-calcium, processo para sua preparação, produto famacêutico derivado e seu uso medicinal |
EP3272336A1 (de) | 2016-07-19 | 2018-01-24 | Stada Arzneimittel Ag | Atorvastatin-zusammensetzung |
-
1996
- 1996-07-08 PT PT96924367T patent/PT848704E/pt unknown
- 1996-07-08 DE DE69616358T patent/DE69616358T2/de not_active Expired - Lifetime
- 1996-07-08 SI SI9630356T patent/SI0848704T1/xx unknown
- 1996-07-08 EP EP96924367A patent/EP0848704B2/de not_active Expired - Lifetime
-
2003
- 2003-03-06 CY CY0300020A patent/CY2356B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE69616358D1 (de) | 2001-11-29 |
EP0848704A1 (de) | 1998-06-24 |
EP0848704B1 (de) | 2001-10-24 |
SI0848704T1 (en) | 2002-04-30 |
EP0848704B2 (de) | 2009-12-16 |
PT848704E (pt) | 2002-03-28 |
DE69616358T2 (de) | 2002-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP960339B1 (en) | Crystalline /r- (r*, r*)/-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-/(phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid hemi calcium salt | |
ZA966043B (en) | Novel process for the production of amorphous [R-(R*,R*)]-2(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acide calcium salt (2:1). | |
TWI319396B (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) | |
BG102186A (en) | Crystalline form iii of hemicalcium salts of [r-(r*, r*)]-2-(4-fluorophenyl)-beta,delta -dyhydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h -ppyrol-1-heptane acid (atorvastatin) | |
HUP0700116A2 (en) | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-betha,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-heptanoic acid calcium salt (2:1) | |
NO975499D0 (no) | Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-<beta>-<delta>-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt | |
CY2356B1 (en) | Form III crystalline {r-(r*,r*)}-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methyl-ethyl)-3-phenyl-4-{(phenylamino)carbonyl}-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin). | |
AU2001234058A1 (en) | Form v crystalline (r-(r*,r*))-2-(4-fluorophenyl)-ss,$g(d)-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1- heptanoic acid hemi calcium salt. (atorvastatin) | |
NZ507836A (en) | Crystalline [r*(r* ,r*)]-2-(4-flurophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |